Ultragenyx Pharma (RARE) Tops Q4 EPS by 3c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Ultragenyx Pharma (RARE) Tops Q4 EPS by 3c, Revenues Beat

Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update

February 13, 2020 4:02 PM EST

2019 total revenue is $103.7 million; 2019 Crysvita® (burosumab) revenue to Ultragenyx is $87.3 million

2020 Crysvita revenue in Ultragenyx territories guidance of $125 million to $140 million reaffirmed

NOVATO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2019 and reaffirmed its financial guidance for 2020.

In 2019 we created a substantial foundation based on the strong launch... More